Member area login
You don't have or don't remember the password!
Click Here
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada

Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282


ISSN print: 0393 – 0564
ISSN digital: 0392- 7091

BC: Articoli scritti da V. Scocco

Antigene carboidratico 125 (CA-125) vs. proteina 4 dell’epididimo umano (HE4) in una popolazione di donne con massa pelvica
Carbohydrate antigen 125 (CA-125) vs. human epididymis protein 4 (HE4) in a population of women with pelvic mass
<p>Aim of this study was to compare the diagnostic performance of CA-125 and HE4 for epithelial ovarian&nbsp;carcinoma (OC) in 505 consecutive women referred to our hospital for an adnexal mass. The population consisted of&nbsp;18 (3.6%) patients with OC (13 in post-menopausal status, 72.2%) and 487 patients with a benign mass (171 in postmenopausal&nbsp;status, 35.1%). Employed diagnostic thresholds were 35 kU/L for CA-125 and 70 or 140 pmol/L for HE4&nbsp;in pre-menopause and post-menopause, respectively. CA-125 and HE4 concentrations were significantly lower in&nbsp;patients with benign mass in comparison to women with OC. Overall sensitivity and specificity were higher for HE4&nbsp;than for CA-125: 94.4% vs. 61.1% (P=0.04) and 91.0% vs. 82.8% (P=0.0002). False positive results for CA-125 and&nbsp;HE4 were found in 16.8% and 6.6% of women in pre-menopause and in 18.1% and 13.5% of women in postmenopause,&nbsp;respectively. Our results confirmed a higher specificity for HE4 vs. CA-125. Thus, the additional&nbsp;evaluation of HE4 would enable a more accurate referral of patients at risk for OC to the gynecological oncology&nbsp;services.</p>
Biochimica Clinica ; 37(3) 190-194
Contributi Scientifici - Scientific Papers